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MCM3AP in recessive Charcot-Marie-Tooth
neuropathy and mild intellectual disability
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Defects in mRNA export from the nucleus have been linked to various neurodegenerative disorders. We report mutations in the
gene MCM3AP, encoding the germinal center associated nuclear protein (GANP), in nine affected individuals from ﬁve unrelated
families. The variants were associated with severe childhood onset primarily axonal (four families) or demyelinating (one family)
Charcot-Marie-Tooth neuropathy. Mild to moderate intellectual disability was present in seven of nine affected individuals. The
affected individuals were either compound heterozygous or homozygous for different MCM3AP variants, which were predicted to
cause depletion of GANP or affect conserved amino acids with likely importance for its function. Accordingly, ﬁbroblasts of
affected individuals from one family demonstrated severe depletion of GANP. GANP has been described to function as an mRNA
export factor, and to suppress TDP-43-mediated motor neuron degeneration in ﬂies. Thus our results suggest defective mRNA
export from nucleus as a potential pathogenic mechanism of axonal degeneration in these patients. The identiﬁcation of MCM3AP
variants in affected individuals from multiple centres establishes it as a disease gene for childhood-onset recessively inherited
Charcot-Marie-Tooth neuropathy with intellectual disability.
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Introduction
Hereditary sensorimotor neuropathies are collectively
known as Charcot-Marie-Tooth disease (CMT). Based on
nerve conduction velocities, the disease can be divided into
demyelinating CMT (CMT1), axonal CMT (CMT2) and
intermediate CMT (Reilly et al., 2011). All forms of
Mendelian inheritance are possible. Autosomal recessive
CMT is typically more severe than the autosomal dominant
forms, often with onset in early childhood and severe
symptoms such as skeletal deformities and loss of ambula-
tion before adulthood (Tazir et al., 2013). Although more
than 70 disease genes for CMT are known, a large number
of affected individuals remain without a genetic diagnosis,
particularly in CMT2, suggesting that undiscovered disease
genes remain (Rossor et al., 2013).
Germinal center associated nuclear protein (GANP) is a
multi-domain 208 kDa protein that localizes predominantly
to the nucleus and is encoded by 28 exons of MCM3AP at
chromosome 21q22.3 (Abe et al., 2000). MCM3AP is ubi-
quitously expressed (Abe et al., 2000), but the exact func-
tions of GANP in various tissues remain incompletely
understood. GANP has been described to serve as a scaf-
fold for transcription export 2 (TREX-2) complex involved
in the export of mRNAs from the nucleus to the cytoplasm
(Wickramasinghe et al., 2010; Umlauf et al., 2013). In add-
ition, GANP may associate with NXF1 (nuclear RNA
export factor 1) to facilitate the transport of mRNAs
from the nuclear interior to the nuclear pores
(Wickramasinghe et al., 2010; Jani et al., 2012). In B
cells, GANP has been shown to favour transcription com-
plex recruitment and chromatin remodelling at rearranged
immunoglobulin variable loci (Singh et al., 2013).
An exome sequencing study by Schuurs-Hoeijmakers
et al. (2013) investigated families with intellectually
disabled siblings, and among their potentially pathogenic
ﬁndings reported a homozygous MCM3AP missense
change p.Glu915Lys in an affected sibling pair with pro-
gressive polyneuropathy. Another recent study proposed
that a de novo p.Pro443Ser variant in MCM3AP in com-
bination with a de novo variant in POMP, encoding a
proteasome maturation protein, led to a DNA repair deﬁcit
in a child who suffered from immune deﬁciency (Gatz
et al., 2016). The pathogenic role of the MCM3AP variants
in the former studies is unclear, and thus this gene has not
yet been conclusively implicated in human disease.
We present here evidence in multiple families, establish-
ing MCM3AP as a disease gene for autosomal recessive
CMT and intellectual disability.
Materials and methods
Patients and sequencing
We studied patients from ﬁve families of Finnish (Family F),
Australian (Family A), Canadian (Family C), Dutch (Family N)
and Turkish (Family T) origin (Fig. 1A). Our study was con-
ducted in accordance with the Declaration of Helsinki, and all
participating individuals or their guardians gave written in-
formed consent to participate. The study was approved by
the institutional ethics boards. The collaboration was partly
established through investigators sharing their genes of interest
through the GeneMatcher (Sobreira et al., 2015).
Whole exome sequencing (WES) was performed for Patients
F:II-3, F:II-4, F:II-5, A:II-2, N:II-1, C:II-1, T:II-1, and T:II-2,
for each family independently. Details of the sequencing meth-
ods are in the Supplementary material. MCM3AP variants
were conﬁrmed by Sanger sequencing; primer sequences are
supplied in the Supplementary material.
Skin fibroblast culture and analysis of
RNA and protein
Fibroblast cultures were established from skin punch biopsies
by standard methods. Following RNA isolation and cDNA
synthesis, cDNA was sequenced with primers speciﬁc for
exons 1–2 and 16–18 for Family F ﬁbroblasts, and exons
9–10 for Family A ﬁbroblasts. Quantitative PCR (qPCR) was
done using DyNAmo
TM
Flash (Thermo Scientiﬁc). Detailed
methods and primer sequences are in the Supplementary ma-
terial. Western blotting was performed with sheep anti-GANP
primary antibody provided by Dr Vihandha Wickramasinghe,
University of Cambridge. To inhibit nonsense-mediated decay
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Figure 1 Pedigrees of affected families and map of variants in MCM3AP/GANP. (A) Family pedigrees. The genotypes are given for
individuals whose samples were available for study, a plus sign ( + ) indicates a normal allele. (B) The human GANP protein belongs to the Sac3/
GANP protein family and consists of 1980 amino acids. The protein contains domains for FG (phenylalanine-glycine) repeat, DNA primase, Sac3
(suppressor of actin 3), CID (Cdc31 interaction domain) and an acetyltransferase domain. The localization of the patient variants in GANP
domains and MCM3AP exons are shown with arrows. Arrowheads indicate the positions of two previously reported MCM3AP variants, de novo
p.Pro443Ser in a child with immunodeficiency, and a homozygous p.Glu915Lys in a sibling pair with intellectual disability. (C) Evolutionary
conservation of the amino acids affected by the detected missense variants.
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(NMD), cells were treated with cycloheximide (CHX) 20mg/
ml (Sigma) for 24 h. Proteasome inhibition with MG132 was
performed as previously described (Ylikallio et al., 2013).
Minigene mRNA splicing assay
MCM3AP exon 5 and ﬂanking intronic sequences were in-
serted into pSPL3 minigene vector (Hansen et al., 2008;
Wang et al., 2015), a kind gift from Dr Thomas v. O.
Hansen. Mutagenesis was used to introduce the splice donor
variant c.1857A4G, p.Q619= into exon 5. Two micrograms
of plasmids containing the mutated or wild-type exon 5 were
transfected into 143B cells with jetPRIME

kit (Polyplus).
RNA was isolated 24 h later with NucleoSpin

kit
(Macherey-Nagel) and RT-PCR performed to detect the effects
on splicing. Details of the experiment and vector map are
supplied in the Supplementary material.
Mixed neuronal cultures from human
induced pluripotent stem cells
To establish a neuronal culture, a previously characterized
human induced pluripotent stem cell (iPSC) line HEL11.4
(Mikkola et al., 2013) was differentiated towards neuronal
lineage according to Hamalainen et al. (2013). Full methods
are included in the Supplementary material. Neuronal cells
were identiﬁed using immunocytochemistry with antibody
against neuron-speciﬁc class III b-tubulin (TUJ1, #801201,
BioSite), and GANP was detected using an N-terminal anti-
body (#ab198173, Abcam).
DNA damage repair
To study DNA damage repair, we used ﬁbroblasts from
Patients F:II-3 and F:II-4. Three unrelated normal ﬁbroblast
lines served as negative controls, and ﬁbroblasts derived
from a xeroderma pigmentosum group C (XPC) patient
(Coriell Institute Cell repository, GM16684) and from a
DNA ligase 4 syndrome (LIG4) patient (Coriell Institute Cell
repository, GM16088) as positive controls for sensitivity to
UV and ionizing radiation, respectively. Experimental details
are provided in the Supplementary material.
Results
Clinical findings
The affected individuals (Fig. 1A) presented with multiple
neurological and variable degrees of non-neurological signs
and symptoms. The clinical features are summarized in
Table 1. Results from nerve conduction studies are given
in Table 2, and detailed case descriptions in the
Supplementary material. Sensorimotor neuropathy was a
prominent feature in all affected individuals. Nerve conduc-
tion studies showed axonal neuropathy in Families F, A, N
and C. In Family T, nerve conduction studies of Subject
T:II-1 was done at an advanced stage of the disease and
thus nerve conduction velocities were unobtainable. In
Patient T:II-2, median motor nerve conduction velocity
was decreased to 23m/s, consistent with a demyelinating
component. Patient N:II-1 also had decreased median nerve
conduction velocities suggesting demyelination in addition
to the axonal degeneration. The affected individuals had
severe and progressive distal muscle weakness and atrophy
in hands and feet. Motor development was delayed, and
independent ambulation was generally lost between ages
10–24 years. Besides CMT, the second most consistent
ﬁnding was intellectual disability, which was found in
seven of nine affected individuals (Supplementary Table
1). The intellectual disability was generally mild to moder-
ate, although more severe intellectual disability was seen in
two older patients in Family C. In addition, two individuals
(Patients F:II-3 and A:II-2) manifested with delayed speech
development and learning difﬁculties.
Genetic findings
Sequencing revealed MCM3AP variants segregating
with the phenotype in all families. The variants in
Family F were a single nucleotide deletion c.443delC
p.Pro148Leufs*48 predicting a frameshift and premature
stop in the FG-repeat domain of GANP (Fig. 1B), and a
missense variant c.3814G4A p.Val1272Met. The frame-
shift variant was not found in the ExAC database, whereas
p.Val1272Met is a European variant with a further enrich-
ment in Finland with population frequencies of 0.0002 and
0.0057, respectively. No homozygous individuals for
the missense variant have been listed in any database.
The Combined Annotation Dependent Depletion (CADD)
version 1.3 (Kircher et al., 2014) C-score of p.Val1272Met
was 10.54. The variants segregated with the disease
phenotype: the three affected individuals carried both
variants, their father was a heterozygous carrier of
p.Pro148Leufs*48 and their mother was heterozygous for
p.Val1272Met. Of the two tested unaffected siblings one
was a heterozygous carrier of p.Val1272Met and the other
carried neither variant (Fig. 1A).
In the affected Patient A:II-2, we found a nonsense vari-
ant c.2667C4A p.Tyr889* and a missense variant
c.2600C4A p.Ala867Asp. Neither variant was present in
ExAC. The p.Ala867Asp variant was maternally inherited,
and the frameshift variant was found to be de novo. This
was conﬁrmed using a second independent sample of the
patient and father, and family relationships were conﬁrmed
using single nucleotide polymorphism (SNP) duo analysis.
The missense change p.Ala867Asp, which locates in the
Sac3 (suppressor of actin 3) domain of GANP (Fig. 1B),
received a CADD C-score of 28.1.
The affected individual from Family N was compound
heterozygous for the c.1857A4G p.Gln619= variant, and
a single nucleotide insertion c.3949_3950insG
p.Asn1317fs*18, both of which were absent in ExAC.
The latter change, located in exon 18, predicted a frame-
shift and a premature stop codon. The c.1857A4G variant
was positioned in the splice donor position of exon 5. In
silico prediction with the Human Splicing Finder version
2096 | BRAIN 2017: 140; 2093–2103 E. Ylikallio et al.
T
a
b
le
1
S
u
m
m
a
r
y
o
f
c
li
n
ic
a
l
fe
a
tu
re
s
o
f
th
e
p
a
ti
e
n
ts
P
a
ti
e
n
t
V
a
ri
a
n
ts
S
e
x
O
ri
g
in
A
g
e
W
a
lk
in
g
L
o
ss
o
f
a
m
b
u
la
ti
o
n
(a
g
e
)
S
e
n
so
ri
-m
o
to
r
n
e
u
ro
p
a
th
y
In
te
ll
e
c
tu
a
l
d
is
a
b
il
it
y
U
M
N
si
g
n
s
B
ra
in
M
R
I
fi
n
d
in
g
s
L
o
w
e
r
li
m
b
re
fl
e
x
e
s
O
th
e
r
F:
II
-3
c.
3
8
1
4
G
4
A
p
.V
al
1
2
7
2
M
e
t,
c.
4
4
3
d
e
lC
p
.P
ro
1
4
8
L
e
u
fs
*4
8
M
Fi
n
la
n
d
1
9
1
5
m
o
1
0
–
1
1
y
Y
e
s
D
iffi
cu
lt
ie
s
in
sp
e
e
ch
an
d
vi
su
o
m
o
to
r
d
ev
e
lo
p
m
e
n
t
+
M
ild
ly
in
cr
e
as
e
d
si
gn
al
in
te
n
si
ty
in
th
e
ri
gh
t
te
m
p
o
ra
l
lo
b
e
A
cc
e
le
ra
te
d
V
e
n
ti
la
to
r-
d
e
p
e
n
d
e
n
t
fr
o
m
ag
e
1
4
,
Sc
o
lio
si
s,
Sh
o
rt
st
at
u
re
F:
II
-4
c.
3
8
1
4
G
4
A
p
.V
al
1
2
7
2
M
e
t,
c.
4
4
3
d
e
lC
p
.P
ro
1
4
8
L
e
u
fs
*4
8
F
Fi
n
la
n
d
1
3
2
3
m
o
1
0
y
Y
e
s
N
o
-
M
ild
ly
in
cr
e
as
e
d
si
gn
al
in
te
n
si
ty
in
te
m
p
o
ra
l
lo
b
e
s
N
o
rm
al
Sh
o
rt
st
at
u
re
F:
II
-5
c.
3
8
1
4
G
4
A
p
.V
al
1
2
7
2
M
e
t,
c.
4
4
3
d
e
lC
p
.P
ro
1
4
8
L
e
u
fs
*4
8
M
Fi
n
la
n
d
8
2
y
St
ill
am
b
u
la
n
t
Y
e
s
Y
e
s
+
N
o
n
e
(a
t
4
y)
D
im
in
is
h
e
d
B
ic
u
sp
id
ao
rt
ic
va
lv
e
an
d
ao
rt
ic
co
ar
ct
at
io
n
,
Sh
o
rt
st
at
u
re
,
le
ft
-s
id
e
d
am
b
ly
o
p
ia
an
d
m
ic
ro
ti
a
w
it
h
h
e
ar
in
g
im
p
ai
rm
e
n
t
A
:II
-2
c.
2
6
0
0
C
4
A
p
.A
la
8
6
7
A
sp
,
c.
2
6
6
7
C
4
A
p
.T
yr
8
8
9
*
F
A
u
st
ra
lia
8
4
y
St
ill
am
b
u
la
n
t
fo
r
sh
o
rt
d
is
ta
n
ce
s
Y
e
s
L
ik
e
ly
-
B
ra
in
n
o
rm
al
,
ce
rv
ic
al
m
ye
lo
m
al
ac
ia
A
b
se
n
t
Se
n
so
ry
at
ax
ia
,
b
u
lb
ar
d
ys
fu
n
ct
io
n
,
sp
e
e
ch
d
e
la
y,
O
SA
N
:II
-1
c.
1
8
5
7
A
4
G
p
.G
ln
6
1
9
=
,
c.
3
9
4
9
_
3
9
5
0
in
sG
p
.A
sn
1
3
1
7
fs
*1
8
F
N
e
th
e
rl
an
d
s
3
N
o
t
am
b
u
la
n
t
Y
e
s
Y
e
s
-
N
o
n
e
(a
t
6
m
o
)
A
b
se
n
t
D
e
cr
e
as
e
d
p
ai
n
se
n
sa
ti
o
n
,
hy
p
o
to
n
ia
,
co
n
ge
n
it
al
p
to
si
s,
ae
so
tr
o
p
ia
,
sc
o
lio
si
s
C
:II
-1
c.
4
4
3
3
C
4
A
p
.S
e
r1
4
7
8
*,
c.
4
7
2
9
G
4
A
p
.G
lu
1
5
7
7
Ly
s
F
C
an
ad
a
2
8
1
7
m
o
1
5
y
Y
e
s;
as
so
ci
at
e
d
co
n
tr
ac
tu
re
s
C
an
re
ad
at
a
gr
ad
e
1
le
ve
l,
n
o
ad
d
it
io
n
,
L
ife
Sk
ill
s
p
ro
gr
am
-
N
o
n
e
A
b
se
n
t
P
ri
m
ar
y
o
va
ri
an
fa
ilu
re
,
st
ra
b
is
m
u
s,
o
b
e
si
ty
C
:II
-2
c.
4
4
3
3
C
4
A
p
.S
e
r1
4
7
8
*,
c.
4
7
2
9
G
4
A
p
.G
lu
1
5
7
7
Ly
s
F
C
an
ad
a
2
7
2
0
m
o
2
4
y
Y
e
s;
as
so
ci
at
e
d
co
n
tr
ac
tu
re
s
C
an
re
ad
at
a
gr
ad
e
3
le
ve
l,
ca
n
d
o
si
m
p
le
ad
d
it
io
n
,
n
o
su
b
tr
ac
ti
o
n
-
M
ild
ve
n
tr
ic
u
lo
m
e
ga
ly
an
d
tw
o
sm
al
l
w
h
it
e
m
at
te
r
cy
st
s
in
th
e
le
ft
p
o
st
e
ro
te
m
p
o
ra
l
p
ar
ie
ta
l
re
gi
o
n
A
b
se
n
t
Se
iz
u
re
s,
p
ri
m
ar
y
o
va
ri
an
fa
ilu
re
,
st
ra
b
is
m
u
s,
ve
lo
p
h
ar
yn
ge
al
in
su
ffi
ci
e
n
cy
,
co
rn
e
al
hy
d
ro
p
s,
d
e
p
re
ss
io
n
,
o
b
e
si
ty
,
d
ys
ar
th
ri
c
sp
e
e
ch
T
:II
-1
c.
2
2
8
5
T
4
C
,
p
.M
e
t7
6
2
T
h
r
M
Tu
rk
ey
2
0
4
y
1
0
y
Y
e
s
Y
e
s
-
N
D
A
b
se
n
t
A
ta
x
ia
T
:II
-2
c.
2
2
8
5
T
4
C
,
p
.M
e
t7
6
2
T
h
r
M
Tu
rk
ey
1
2
1
y
?
Y
e
s
Y
e
s
-
N
D
A
b
se
n
t
-
A
ge
=
ag
e
at
la
st
e
x
am
;
W
al
k
in
g
=
ag
e
at
w
h
ic
h
p
at
ie
n
t
le
ar
n
e
d
to
w
al
k
in
d
e
p
e
n
d
e
n
tl
y
o
r
w
it
h
a
w
al
k
in
g
ai
d
;
U
M
N
=
u
p
p
e
r
m
o
to
r
n
e
u
ro
n
;
N
D
=
n
o
t
d
e
te
rm
in
e
d
;
O
SA
=
o
b
st
ru
ct
iv
e
sl
e
e
p
ap
n
o
e
a;
?
=
n
o
t
k
n
o
w
n
;
m
o
=
m
o
n
th
s;
y
=
ye
ar
s.
MCM3AP in axonal neuropathy BRAIN 2017: 140; 2093–2103 | 2097
3.0 suggested that the variant creates an exonic splicing
silencer site, suggesting a splicing defect with a likely con-
sequence on mRNA stability.
In Family C, the siblings were compound heterozygous
for a nonsense variant c.4433C4A p.Ser1478* in exon 21,
and a missense variant c.4729G4A p.Glu1577Lys. The
stop variant was not included in ExAC, whereas the mis-
sense variant was present twice (frequency 1.653  105)
with a CADD score of 24.4. Sanger sequencing conﬁrmed
the variants in the affected siblings, and their unaffected
mother was a carrier of the nonsense variant.
Finally, in Family T two siblings were homozygous for
the missense variant c.2285T4C p.Met762Thr in exon 8.
This variant was not present in ExAC, but a variant in the
same codon, p.Met762Leu, had a carrier frequency of
1.651  105. The p.Met762Thr variant received a
CADD C-score of 25.4.
All MCM3AP variants and the evidence of their patho-
genicity are summarized in Supplementary Table 2.
MCM3AP variants lead to severe
depletion of GANP protein
Skin ﬁbroblasts from affected Patients F:II-3, F:II-4 and
A:II-2 in Families F and A were available for testing the
effects of the compound heterozygosity on mRNA and pro-
tein level. The presence of nonsense variants in these two
families suggested the possibility of NMD. Unexpectedly in
Family F, the sequencing of MCM3AP cDNA showed that
mRNAs containing variants c.443delC or c.3814G4A
were present in the ﬁbroblasts of the affected individuals
(Fig. 2A). Therefore, the nonsense variant c.443delC at
least partially escaped NMD, possibly due to its location
in exon 1. Variants in the ﬁrst exon of a gene may escape
NMD as the result of inability to recruit essential NMD
factors to exon 1 termination sites, enabling translation to
start from an alternative downstream start site (Kozak,
1987; Neu-Yilik et al., 2011). Western blots showed no
smaller bands below the full length GANP, suggesting
that the frameshift mRNA in Family F did not produce a
stable truncated protein (Fig. 2C). However, we found the
total MCM3AP mRNA levels to be reduced to 50%
and GANP protein levels to 20% of the control levels
(Fig. 2B–D). As both alleles could still be detected by
cDNA sequencing, it is likely that both mutations partially
contributed to the mRNA and protein instability. The level
of GANP was not restored by inhibiting the proteasome
with MG132, suggesting a mechanism other than protea-
somal degradation (Fig. 2D). Hence in Family F, the com-
pound heterozygosity of the mutations results in a severe
reduction in the amount of GANP protein.
Sequencing of ﬁbroblast cDNA from Patient A:II-2
showed homozygosity for the c.2600C4A p.(Ala867Asp)
variant. Accordingly, the total MCM3AP mRNA level was
50% of control level (Fig. 2B). Treatment of Patient A:II-
2 ﬁbroblasts with the NMD inhibitor CHX restored the
stability of the nonsense mutant mRNA (Fig. 2A). This
showed that the c.2667C4A p.Tyr889* mRNA was
degraded through NMD, as expected when the stop
codon is in the middle of the gene. The level of GANP
was also decreased in patient’s cells but only to 85% of
the control levels (Fig. 2C and D), potentially as a result of
compensatory increase in the stability of the protein
produced by the missense allele.
Skin ﬁbroblasts from other affected individuals were not
available for investigation of the effects of the identiﬁed
variants. It is, however, noteworthy that also in Family
C, one of the compound heterozygous variants is predicted
to directly affect the GANP protein level through mRNA
instability, and in Family N, a frameshift variant was found
in combination with a probable splicing variant. Using a
minigene splicing assay, we conﬁrmed that the donor splice
site mutation in exon 5 causes the skipping of that exon
(Fig. 2E), resulting in a frameshift and a premature stop
codon p.Ser557fs21*. The minigene assay suggested that
the mutant transcript is in part spliced normally, therefore
some functional protein is likely to be produced. The mis-
sense variants found in Families A, C and T affected con-
served residues (Fig. 1C) and received high pathogenicity
prediction scores. The variants p.Ala867Asp (Family A)
and p.Met762Thr (Family T) localize to the Sac3 domain
(Fig. 1B), needed for interaction with TREX-2 components,
while p.Glu1577Lys (Family C) is in the C-terminal region
of GANP, which is needed for localization to the nuclear
envelope (Jani et al., 2012). The missense variants are
therefore expected to be deleterious for protein function,
but their functional effects need to be addressed in future
studies. Particularly, the association of the homozygous
p.Met762Thr variant with demyelinating CMT requires
conﬁrmation in additional families. In conclusion, our re-
sults suggest that the mechanisms of disease variants in our
affected individuals are related to partial depletion of the
GANP protein and/or its loss of function.
GANP localizes to the nuclear envel-
ope in cultured human neurons
The function of GANP has not been previously investigated
in the human nervous system. It is reported as a ubiquitously
expressed protein (Abe et al., 2000) and we conﬁrmed by
immunocytochemistry in human iPSCs differentiated towards
a neuronal lineage that it is also expressed in human neu-
rons. Neurons detected by co-staining with neuron-speciﬁc
marker TUJ1 showed punctate immunoreactivity of GANP
at the nuclear envelope (Fig. 2F), consistent with its
described role in nuclear pore complexes.
Severe depletion of GANP does not
compromise DNA repair
MCM3AP has previously been linked to a DNA repair
defect (Gatz et al., 2016), and thus we asked if the
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signiﬁcant depletion of GANP observed in the cells from
affected individuals in Family F led to sensitivity to DNA
damage. When subjected to UV or ionizing radiation treat-
ment, the cells from Patients F:II-3 and F:II-4 behaved simi-
lar to healthy control cells, and no defect in the repair of
DNA damage could be identiﬁed (Supplementary Fig. 1).
This result indicates that severe depletion of GANP does
not impair the ability to repair these types of DNA damage.
Discussion
Our results demonstrate that MCM3AP mutations cause
early-onset recessive CMT with intellectual disability.
Variable additional clinical features included pyramidal
signs and brain MRI abnormalities. Affected individuals
in Family C had primary ovarian failure and Patient
F:II-4 had increased gonadotropin levels; however, gonado-
tropin levels were not measured in the other affected
individuals and thus we cannot conclude that gonadal
failure is a consequence of the MCM3AP variants. The
sensorimotor neuropathy was predominantly axonal
except in Family T, where decreased nerve conduction velo-
cities suggested demyelination. Indications of demyelination
were also detected in Patients C:II-2 and N:II-1. Thus,
recessive loss-of-function variants in MCM3AP should be
considered as a cause in patients with either axonal or
demyelinating features and autosomal recessive inheritance
(CMT4). Variants in GDAP1 can also cause demyelinating
CMT4A (Baxter et al., 2002), axonal CMT2K (Cuesta
et al., 2002; Claramunt et al., 2005), or intermediate
CMT type A (Nelis et al., 2002). The causality of either
axonal, demyelinating or intermediate phenotypes is also
well documented for variants in MPZ (Shy et al., 2004).
Similarly, NEFL variants cause predominantly axonal neur-
opathy but nerve conduction velocities can sometimes be
decreased to the CMT1 range (Mersiyanova et al., 2000;
Jordanova et al., 2003). GJB1 is another gene associated
with both axonal and demyelinating forms (Ionasescu
et al., 1994). The identiﬁcation of both axonal and demye-
linating phenotypes for the same disease gene suggests a
defect in the interplay between axons and glia. It is also
possible that the observed decrease of nerve conduction velo-
cities in the patients reported here is caused by loss of mye-
lin that develops secondary to severe degeneration of axons.
Neuropathy has been described as a common comorbid-
ity in intellectual disability (Chiurazzi and Pirozzi, 2016).
However, it is uncommon for affected individuals diag-
nosed with CMT to have concomitant intellectual disabil-
ity. For MFN2 variants, which are the most common cause
of CMT2 (CMT2A2) (Zuchner et al., 2006; Rossor et al.,
2013), cases of intellectual disability and cerebral MRI
abnormalities together with CMT have been reported
(Brockmann et al., 2008; Del Bo et al., 2008; Tufano
et al., 2015). Variants in DYNC1H1 are known to cause
a spectrum of diseases that includes spinal muscular atro-
phy with lower extremity predominance (SMA-LED)
(Harms et al., 2012), intellectual disability with malforma-
tions of cortical development (MCD) (Poirier et al., 2013),
and CMT2O (Weedon et al., 2011). Speech delay and/or
learning difﬁculties were reported in some individuals with
SMA-LED or CMT2O (Weedon et al., 2011; Harms et al.,
2012), and several individuals with MCD also had
neuropathy (Poirier et al., 2013). Furthermore, Cowchock
syndrome (CMTX4) consists of CMT in combination with
intellectual disability and sensorineural hearing loss
(Cowchock et al., 1985). Lastly, giant axonal neuropathy
is a disorder caused by recessively inherited variants in
GAN (Bomont et al., 2000), which can present with a
severe CMT2-resembling neuropathy and multiple add-
itional symptoms and signs including curly hair, CNS
manifestations and intellectual disability (Vijaykumar
et al., 2015). Our ﬁndings add MCM3AP to the disease
genes associated with CMT and intellectual disability.
Table 2 Motor nerve conduction studies
Patient Age Median Ulnar Lower limb
Latency (ms) Amp (mV) CV (m/s) Latency (ms) Amp (mV) CV (m/s) Latency (ms) Amp (mV) CV (m/s)
F:II-3 8 y 3 m - - No response 5.7 (distal) 0.3 (distal) 51 5.8 (distal) 0.3 (distal) 38
0.5 (prox) 0.3 (prox)
F:II-4 1 y 10 m - - - - - - 5.6 (distal) - 38
F:II-5 2 y 1 m 4.1 (distal) 0.7 28.1 - - - 4.0 1.4 26.3
A:II-2 8 y 7.0 0.26 (distal) - 6.6 (distal) 0.47 (distal) 30 7.1 (distal) 0.55 (distal) 28
12.9 (prox) 0.25 (prox) 17.0 (prox) 0.16 (prox)
N:II-1 2 y 8 m 9.44 (distal) 0.10 (distal) 15.3 4.39 (distal) 0.75 (distal) 37 - - -
17.6 (prox) 0.11 (prox) 8.71 (prox) 0.43 (prox)
C:II-1 - - - - - - - - - -
C:II-2 - - - - - - - - - -
T:II-1 15 y - - Unobtainable - - - - - Unobtainable
T:II-2 7 y - 0.5 23 - - - - - -
Amp = amplitude; CV = conduction velocity; m = months; prox = proximal; y = years; - = no record available.
For affected individuals in Family C, nerve conduction studies showed axonal sensorimotor neuropathy, but records of the specific measurements are not available. The lower limb
recordings were from tibial nerve in Patient A:II-2 and from peroneal nerve in Patients F:II-3, F:II-4 and F:II-5.
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Figure 2 Consequences of MCM3AP variants on mRNA and protein level. (A) Sequencing traces for the variants in Families F and A.
Total blood DNA and fibroblast cDNA sequencing traces are shown for Family F. The presence of both variants c.443delC p.Pro148fs48* and
c.3814G4A p.Val1272Met were detected in the cDNA. Sequencing of Family A patient fibroblast cDNA showed that the variant c.2667C4A
p.Tyr889* was undetectable under normal culture conditions, and the cDNA was homozygous for the c.2600C4T p.Ala867Asp variant.
Treatment of fibroblasts with the nonsense mediated decay (NMD) inhibitor cycloheximide (CHX) restored stability of the mRNA containing the
c.2667C4A variant. (B) MCM3AP mRNA levels in fibroblasts from affected individuals in Families F and A, and from controls. The quantification is
shown for three biological triplicates. Mean is indicated by a line. (C) Western blotting results show the relative level of GANP protein (208 kDa)
in patient and control fibroblasts. The 37 kDa GAPDH was detected as a loading control. (D) Quantification of GANP protein level relative to
GAPDH in patient and control cells. Black symbols show the results from three independent blots. Mean is indicated by a line. White circles are
the quantifications from a blot of cells treated with proteasome inhibitor MG132. (E) Minigene splicing assay using the pSPL3-vector containing
MCM3AP exon 5 and flanking intronic sequences revealed that the exon 5 splice donor variant c.1857A4G, p.Gln619=, resulted in skipping of
exon 5. 143B cells transfected with wild-type or mutant plasmids were subjected to RT-PCR using the vector primers. The 454 bp product
resulted from correctly spliced transcript, and the 263 bp product from the exon skipping transcript. Biological triplicates are shown. (F) Mixed
neuronal culture differentiated from human iPSCs co-immunostained with GANP antibody (green) and neuronal marker TUJ1 (red), and with
DAPI (blue). White arrows indicate a neuron, while red arrows indicate other cell types. Scale bars = 10 mm.
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The identiﬁcation of variants in ﬁve families of various
ethnicities suggests that MCM3AP may not be an uncom-
mon disease gene for this clinical presentation.
Our results suggest that GANP has an important role in
the development of the nervous system in addition to its
previously identiﬁed physiologic role in B cell antibody mat-
uration (Singh et al., 2013). GANP expression has been de-
tected in the brain (Abe et al., 2000), but its function in
neural cells has not been characterized. We show that
GANP localizes to the nuclear envelope in cultured human
neurons. Involvement in DNA repair has been suggested for
GANP (Eid et al., 2014; Gatz et al., 2016) as well as for
another recently identiﬁed CMT gene MORC2 (Li et al.,
2012; Albulym et al., 2016; Sevilla et al., 2016), suggesting
these genes may share a common pathway as the underlying
cause for CMT. However, our results in this study do not
support a role for a DNA repair defect in GANP deﬁciency.
Interestingly, a study in Drosophila identiﬁed the orthologue
of MCM3AP, xmas-2, to suppress the toxic effect of cyto-
plasmic accumulation of TDP-43 (TAR DNA binding pro-
tein 43kDa, encoded by TBPH) in ﬂy motor neurons, ﬁtting
with xmas-2 having a crucial role in the nuclear export of
TBPH mRNA in neurons (Sreedharan et al., 2015). GANP
could thus be involved in the regulation of mRNA export
also in human neurons. Defects of RNA metabolism have
been previously implicated in motor neuron degeneration
(Strong, 2010). In particular, GLE1, which is mutated in
foetal motor neuron disease (Nousiainen et al., 2008) or
amyotrophic lateral sclerosis (ALS) (Kaneb et al., 2015), en-
codes a factor that is essential for mRNA export (Folkmann
et al., 2013). Moreover, a recent study showed that dis-
ordered nucleocytoplasmic transport may contribute to
the neurodegeneration caused by protein aggregates in the
cytoplasm (Woerner et al., 2016). Thus, it is conceivable
that GANP dysfunction leading to nuclear retention of
mRNAs that are crucial for neuronal function is the
cause of axonal degeneration in our affected individuals.
Further studies are needed to elucidate the identity of the
particular mRNAs, or other potential roles of GANP in
neurons.
In summary, we have identiﬁed recessive mutations
MCM3AP associated with neuropathy and intellectual
disability and a functional decrease of GANP protein.
Our ﬁndings propose a new molecular mechanism for neur-
opathy involving mRNA export from the nucleus.
Web resources
GeneMatcher, http://www.genematcher.org
Exome Aggregation Consortium (ExAC), http://exac.broad-
institute.org/
Combined Annotation Dependent Depletion (CADD),
http://cadd.gs.washington.edu/home
Human Splicing Finder, http://www.umd.be/HSF3/
HAL Splice Prediction, http://splicing.cs.washington.edu/SE
OMIM, http://www.omim.org/
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